Checkpoint inhibitor-induced lichen planus differs from spontaneous lichen planus on the clinical, histological, and gene expression levelCapsule Summary

• Main Authors: Barbara Meier-Schiesser, MD, PhD (Author), Christine Zecha, MD (Author), Sarah Zierold, MD (Author), Isabel Kolm, MD (Author), Magdalena Röckel, MD (Author), Waltraud Fröhlich (Author), Nora Mittag, MD (Author), Christina Schmitt, MD (Author), Joerg Kumbrink, PhD (Author), Jessica C. Hassel, MD (Author), Carola Berking, MD (Author), Dorothee Nashan, MD (Author), Lars Einar French, MD (Author), Julio Vera-González, PhD (Author), Reinhard Dummer, MD (Author), Katrin Kerl-French, MD (Author), Lucie Heinzerling, MD, MPH (Author)
• Format: Book
• Published: Elsevier, 2024-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Although highly efficacious, immune checkpoint inhibitors induce a multitude of immune-related adverse events including lichenoid skin reactions (irLP) that are often therapy-resistant. Objectives: To compare the clinical, histological, and transcriptional features of irLP with spontaneo...